receby certify that this correspondence is being deposited with the United States with Service as first class mail in an envelope addressed to:

Attorney Docket No.: 019957-011213US

Client Ref. No.: NEO00018C2

Customer No.: 20350

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

MAR 1 4 2005

On March 8, 2005

TOWNSEND and TOWNSEND and CREW LLP

Jo Ann Honcik Dallara

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PAULSON et al.

Application No.: 10/081,456

Filed: February 21, 2002

For: PRACTICAL IN VITRO

SIALYLATION OF RECOMBINANT

**GLYCOPROTEINS** 

Confirmation No. 5830

Examiner:

Rao, Manjunath N.

Art Unit:

1652

**COMMUNICATION UNDER** 

37 C.F.R. §§ 1.821-1.825

<u>AND</u>

**AMENDMENT** 

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action, mailed October 8, 2004, Applicants submit that the computer-readable form in the instant application is identical with the Sequence Listing submitted for Application No. 09/007,741, filed August 27, 1999. In accordance with 37 C.F.R. § 1.821(e), please use the computer-readable form filed in Application No. 09/007,741 as the computer-readable form for the instant application. The information in the paper copy of the

Appl. No. 10/081,456 Amdt. dated March 8, 2005 Reply to Office Action of October 8, 2004

Sequence Listing enclosed herewith is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Specification begin on page 3 of this paper.

Remarks begin on page 4 of this paper.